Arrixardo (Tablets) Instructions for Use

ATC Code

B01AF01 (Rivaroxaban)

Active Substance

Rivaroxaban (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Anticoagulant – direct factor Xa inhibitor

Pharmacotherapeutic Group

Antithrombotic agents; direct factor Xa inhibitors

Pharmacological Action

A selective, direct inhibitor of factor Xa for oral administration. The activation of factor X to form factor Xa via the intrinsic and extrinsic pathways plays a central role in the coagulation cascade.

Rivaroxaban has a dose-dependent effect on prothrombin time and is characterized by a high correlation with plasma concentration when analyzed using the Neoplastin kit (results will differ when using other reagents).

Rivaroxaban also dose-dependently increases aPTT and the HepTest result; however, these parameters are not recommended for assessing the pharmacodynamic effects of rivaroxaban.

Pharmacokinetics

After oral administration, Rivaroxaban is rapidly absorbed; the absolute bioavailability is high and amounts to 80-100%. C_max in plasma is reached within 2-4 hours. Food intake does not affect the AUC and C_max of rivaroxaban.

The pharmacokinetics of rivaroxaban are characterized by moderate variability; inter-individual variability (coefficient of variation) is 30-40%, except on the day of surgery and the following day, when variability is high (70%).

Plasma protein binding, predominantly with albumin, is 92-95%. V_d is approximately 50 L.

Rivaroxaban is eliminated primarily as metabolites (approximately 2/3 of the dose), with half being excreted renally and the other half via feces. One-third of the administered dose undergoes direct renal excretion as unchanged substance, believed to be primarily via active renal secretion.

The metabolism of rivaroxaban occurs with the involvement of the isoenzymes CYP3A4, CYP2J2, as well as enzymes independent of the cytochrome P450 system. The main sites of biotransformation are the morpholine group, undergoing oxidative decomposition, and the amide groups, undergoing hydrolysis.

According to in vitro data, Rivaroxaban is a substrate for the transporter proteins P-gp (P-glycoprotein) and BCR-P (breast cancer resistance protein). Unchanged Rivaroxaban is the most significant compound in human plasma; no active circulating metabolites have been detected in plasma.

The systemic clearance of rivaroxaban is approximately 10 L/h. The terminal T_1/2 in young patients is 5-9 hours, and in elderly patients, it is 11-13 hours.

In elderly patients, plasma concentrations of rivaroxaban are higher than in young patients, with the mean AUC being approximately 1.5 times higher than the corresponding values in young patients, mainly due to reduced total and renal clearance.

In patients with mild (CrCl ≤80-50 mL/min), moderate (CrCl ≤50-30 mL/min), or severe (CrCl ≤30-15 mL/min) renal impairment, AUC values were 1.4, 1.5, and 1.6 times higher, respectively, than in healthy volunteers. The corresponding increase in pharmacodynamic effect was more pronounced.

Indications

Adults: prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation; treatment of deep vein thrombosis and pulmonary embolism and prevention of recurrent DVT and PE.

Children: treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in children and adolescents under 18 years of age with a body weight of 30 kg or more after at least 5 days of initial parenteral anticoagulant therapy.

ICD codes

Dosage Regimen

Administer the 10 mg and 15 mg tablets with food. The 20 mg tablet must be taken with a meal to ensure adequate absorption.

For stroke prevention in non-valvular atrial fibrillation, the recommended dose is 20 mg once daily. For patients with moderate renal impairment (CrCl 30-49 mL/min), reduce the dose to 15 mg once daily.

For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), the initial dose is 15 mg twice daily for the first 21 days. Following this, continue with a 20 mg once daily maintenance dose.

For the prevention of recurrent DVT and PE, the recommended long-term dose is 20 mg once daily.

In pediatric patients (≥30 kg body weight) for VTE treatment and recurrence prevention, administer 20 mg once daily after at least 5 days of initial parenteral anticoagulation. Do not use the 20 mg tablet in children and adolescents weighing less than 50 kg.

Do not use in patients with severe renal impairment (CrCl <15 mL/min). Use with caution in patients with moderate renal impairment (CrCl 30-49 mL/min) who are also taking drugs that increase rivaroxaban plasma levels.

If a dose is missed, take it as soon as possible on the same day. Do not double the dose to make up for a forgotten one.

Discontinue rivaroxaban at least 24 hours before an invasive procedure or surgery if the clinical condition permits. Decide on the timing of re-initiation after a procedure based on clinical assessment and adequate hemostasis.

Adverse Reactions

Given the pharmacological mechanism of action, the use of rivaroxaban may be associated with an increased risk of occult or overt bleeding from any organ or tissue, which may lead to post-hemorrhagic anemia. The signs, symptoms, and severity (including the possibility of a fatal outcome) will vary depending on the location and severity or duration of the bleeding. The risk of bleeding may be increased in certain patient groups, for example, patients with uncontrolled severe arterial hypertension and/or in patients taking drugs that affect hemostasis. Hemorrhagic complications may manifest as weakness, asthenia, pallor, dizziness, headache, or edema of unclear etiology. Therefore, when assessing the condition of a patient receiving anticoagulants, the likelihood of bleeding should be assessed.

From the blood and lymphatic system: common – anemia; uncommon – thrombocythemia.

From the cardiovascular system: common – post-procedural hemorrhage (including postoperative anemia and wound bleeding); uncommon – tachycardia, arterial hypotension (including procedural hypotension), hemorrhage (including hematomas and rare cases of muscle hemorrhage), gastrointestinal hemorrhages (including hematemesis, gingival bleeding, rectal bleeding, hematuria, genital bleeding, epistaxis).

From the digestive system: common – nausea; uncommon – constipation, diarrhea, abdominal pain, gastric discomfort, dyspepsia, dry mouth, vomiting; rare – impaired liver function.

Other: uncommon – localized or peripheral edema, fatigue, weakness, asthenia, fever.

Allergic reactions: uncommon – urticaria (including cases of generalized urticaria); rare – allergic dermatitis.

From the CNS: uncommon – dizziness, headache, syncope.

From the musculoskeletal system: uncommon – pain in extremity.

Dermatological reactions: uncommon – pruritus (including cases of generalized pruritus), skin rash.

From the urinary system: uncommon – renal failure (increased blood creatinine, urea).

From laboratory tests: common – increased LDH level, increased ALT and AST levels; uncommon – increased levels of lipase, amylase, blood bilirubin, ALP level; rare – increased level of conjugated bilirubin (with or without concomitant increase in liver transaminases).

Contraindications

Hypersensitivity to rivaroxaban; clinically significant active bleeding (e.g., intracranial bleeding, gastrointestinal bleeding); lesion or condition associated with an increased risk of major bleeding, for example, existing or recently experienced gastrointestinal ulcer, presence of malignant neoplasms with a high risk of bleeding, recent trauma to the brain or spinal cord, surgery on the brain, spinal cord or eyes, intracranial hemorrhage, diagnosed or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or pathology of the vessels of the brain or spinal cord; concomitant therapy with any other anticoagulants, for example, unfractionated heparin, low molecular weight heparins (including enoxaparin, dalteparin), heparin derivatives (including fondaparinux), oral anticoagulants (including warfarin, apixaban, dabigatran), except when switching from or to Rivaroxaban or when using unfractionated heparin in doses necessary to maintain the function of a central venous or arterial catheter; liver disease accompanied by coagulopathy and the risk of clinically significant bleeding, including patients with liver cirrhosis (Child-Pugh class B and C); severe renal impairment (CrCl <15 mL/min); pregnancy, breastfeeding period; children and adolescents under 18 years of age with body weight less than 30 kg – for the 15 mg dose, children and adolescents under 18 years of age with body weight less than 50 kg – for the 20 mg dose.

With caution

When treating patients with an increased risk of bleeding (including with congenital or acquired bleeding tendency, uncontrolled severe arterial hypertension, gastric and duodenal ulcer in the acute phase, recently experienced gastric and duodenal ulcer, vascular retinopathy, bronchiectasis or history of pulmonary hemorrhage); when treating patients with moderate renal impairment (CrCl 30-49 mL/min) receiving concomitant drugs that increase the plasma concentration of rivaroxaban; when treating patients with severe renal impairment (CrCl 15-29 mL/min); in children and adolescents with moderate or severe renal impairment (eGFR<50 mL/min/1.73 m²); in patients receiving concomitant medications that affect hemostasis, for example, NSAIDs, antiplatelet agents, other antithrombotic agents or selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs); in patients receiving concomitant treatment with systemic azole antifungal drugs (e.g., ketoconazole, itraconazole, voriconazole or posaconazole) or HIV protease inhibitors (e.g., ritonavir).

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and breastfeeding.

Use in Hepatic Impairment

Contraindicated in liver disease accompanied by coagulopathy that increases the risk of clinically significant bleeding, including patients with liver cirrhosis (Child-Pugh class B and C).

Use in Renal Impairment

Contraindicated in patients with severe renal failure (CrCl ≤15 mL/min).

Rivaroxaban should be used with caution when treating patients with moderate renal impairment (CrCl 30-49 mL/min) receiving concomitant therapy with drugs that can cause an increase in the plasma concentration of rivaroxaban, as well as in patients with CrCl ≤15-30 mL/min. In patients with severe renal impairment, the plasma concentration of rivaroxaban may be significantly increased, which may lead to an increased risk of bleeding.

Patients with severe renal impairment at increased risk of bleeding after initiation of treatment should be closely monitored for the timely detection of hemorrhagic complications. Such monitoring may include regular physical examination of the patient, careful monitoring of surgical wound drainage, and periodic determination of hemoglobin levels.

Pediatric Use

Used in children and adolescents under 18 years of age according to indications.

Contraindicated in children and adolescents under 18 years of age with body weight less than 30 kg – for the 15 mg dose, in children and adolescents under 18 years of age with body weight less than 50 kg – for the 20 mg dose.

Geriatric Use

No dose adjustment is required when used in elderly patients.

Special Precautions

The use of rivaroxaban is not recommended in patients with severe renal impairment (CrCl ≤15 mL/min).

Rivaroxaban should be used with caution when treating patients with moderate renal impairment (CrCl 30-49 mL/min) receiving concomitant therapy with drugs that can cause an increase in the plasma concentration of rivaroxaban, as well as in patients with CrCl ≤15-30 mL/min. In patients with severe renal impairment, the plasma concentration of rivaroxaban may be significantly increased, which may lead to an increased risk of bleeding.

Patients with severe renal impairment at increased risk of bleeding and patients receiving concomitant systemic therapy with azole antifungals or HIV protease inhibitors, after initiation of treatment, should be under close supervision for the timely detection of hemorrhagic complications. Such monitoring may include regular physical examination of the patient, careful monitoring of surgical wound drainage, and periodic determination of hemoglobin levels.

Rivaroxaban should be used with caution when treating patients with an increased risk of bleeding, including those with congenital or acquired conditions leading to bleeding; uncontrolled severe hypertension; active peptic ulcer of the gastrointestinal tract; recently experienced peptic ulcer of the gastrointestinal tract; vascular retinopathy; recently experienced intracranial or intracerebral hemorrhage; intraspinal or intracerebral vascular pathology; recently undergone neurosurgery (surgery on the brain, spinal cord) or ophthalmic surgery.

Caution is required when prescribing rivaroxaban to patients receiving medications that affect hemostasis, such as NSAIDs, platelet aggregation inhibitors, or other antithrombotic agents.

When use in children is necessary according to indications and in the appropriate dosage form, the risk of bleeding should be carefully assessed before and during treatment with rivaroxaban.

Drug Interactions

Concomitant use of rivaroxaban and strong inhibitors of the CYP3A4 isoenzyme and P-glycoprotein may lead to a decrease in renal and hepatic clearance and thus significantly increase the AUC of rivaroxaban.

Concomitant use of rivaroxaban and the azole antifungal drug ketoconazole (400 mg once daily), a strong inhibitor of CYP3A4 and P-glycoprotein, resulted in a 2.6-fold increase in the mean steady-state AUC of rivaroxaban and a 1.7-fold increase in the mean C_max of rivaroxaban, accompanied by a significant enhancement of the drug’s pharmacodynamic effects.

Concomitant use of rivaroxaban and the HIV protease inhibitor ritonavir (600 mg twice daily), a strong inhibitor of CYP3A4 and P-glycoprotein, resulted in a 2.5-fold increase in the mean steady-state AUC of rivaroxaban and a 1.6-fold increase in the mean C_max of rivaroxaban, accompanied by a significant enhancement of the drug’s pharmacodynamic effects. Therefore, Rivaroxaban should be used with caution when treating patients simultaneously receiving systemic azole antifungal drugs or HIV protease inhibitors.

Clarithromycin (500 mg twice daily), a potent inhibitor of CYP3A4 and a moderate inhibitor of P-glycoprotein, caused a 1.5-fold increase in mean AUC values and a 1.4-fold increase in C_max of rivaroxaban. This increase in AUC and C_max is within the normal range and is considered clinically insignificant.

Erythromycin (500 mg three times daily), a moderate inhibitor of the CYP3A4 isoenzyme and P-glycoprotein, caused a 1.3-fold increase in mean steady-state AUC and C_max values of rivaroxaban. This increase in AUC and C_max is within the normal range and is considered clinically significant.

Concomitant administration of rivaroxaban and rifampicin, a potent inducer of CYP3A4 and P-glycoprotein, led to an approximately 50% decrease in the mean AUC of rivaroxaban and a parallel decrease in its pharmacodynamic effects. Concomitant use of rivaroxaban with other potent inducers of CYP3A4 (e.g., phenytoin, carbamazepine, phenobarbital, or St. John’s wort preparations) may also lead to a decrease in rivaroxaban plasma concentrations. The decrease in rivaroxaban plasma concentration is considered clinically insignificant.

After combined use of enoxaparin (in a single dose of 40 mg) and rivaroxaban (in a single dose of 10 mg), an additive effect on anti-factor Xa activity was observed, which was not accompanied by additional effects on blood coagulation parameters (prothrombin time, aPTT). Enoxaparin did not alter the pharmacokinetics of rivaroxaban.

No pharmacokinetic interaction was identified between rivaroxaban and clopidogrel (loading dose of 300 mg followed by a maintenance dose of 75 mg), but in a subgroup of patients, a clinically significant increase in bleeding time was detected, which did not correlate with platelet aggregation and the level of P-selectin or GPIIb/IIIa receptor.

After simultaneous administration of rivaroxaban and 500 mg of naproxen, no clinically relevant prolongation of bleeding time was observed. However, a more pronounced pharmacodynamic response is possible in individual subjects.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.